Nortech Systems to Report Third Quarter Results November 14
Quarterly Conference Call November 15 at 10:00 a.m. (CT) 877-407-0782
MINNEAPOLIS--(BUSINESS WIRE)-- Nortech Systems Incorporated (NASDAQ: NSYS) will hold a conference call at 10:00 a.m. (CT) on Thursday, November 15, 2018, to discuss the company’s third quarter results, which will be released on November 14. Anyone interested in participating in the conference can access the call by dialing 877-407-0782 from within the United States, or 201-689-8567 if calling internationally.
An audio webcast and replay of this conference call can be accessed at the investor relations portion of Nortech Systems’ website at www.nortechsys.com or at www.investorcalendar.com. The telephone replay will be available through November 29, 2018, by dialing 877-481-4010 (from U.S.) or 919-882-2331 (International). To access the replay, the conference ID 40286 is required.
About Nortech Systems Incorporated
Nortech
Systems (www.nortechsys.com),
based in Maple Grove, Minn., is a full-service electronics manufacturing
services (EMS) provider of complex interconnect solutions, printed
circuit board assemblies and diagnostic repair and integration services
including higher-level assemblies and box builds for a wide range of
industries. Markets served include industrial and commercial equipment,
medical device, and aerospace & defense. Nortech has a range of
specialized, high-tech facilities in the U.S., Latin America and Asia
used for customized design, manufacture, testing and repair of its
solutions. Nortech Systems is traded on the NASDAQ Stock Market under
the symbol NSYS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181108006030/en/
Brookside Communications Group
Warren Djerf, 952-920-3908
[email protected]
Source: Nortech Systems Incorporated
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ciena beats estimates on strong AI-driven demand, shares rise
- CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
- Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share